Clinical Trials Directory

Trials / Completed

CompletedNCT02385240

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
552 (actual)
Sponsor
Padagis LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.

Conditions

Interventions

TypeNameDescription
DRUGBrimonidine Topical Gel, 0.33 percent (Perrigo)
DRUGBrimonidine Topical Gel, 0.33 percent (Reference)
DRUGPlacebo gel

Timeline

Start date
2015-03-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2015-03-11
Last updated
2021-10-22
Results posted
2020-12-14

Source: ClinicalTrials.gov record NCT02385240. Inclusion in this directory is not an endorsement.

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea (NCT02385240) · Clinical Trials Directory